- Home
- SAN vs AMGN Comparison
SAN vs AMGN Comparison
Compare SAN & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAN | AMGN |
|---|---|---|
| Founded | 1857 | 1980 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.6B | 224.2B |
| IPO Year | 1994 | 2002 |
Fundamental Metrics
Financial Performance| Metric | SAN | AMGN |
|---|---|---|
| Price | $11.48 | $468.53 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 34 |
| Target Price | $14.56 | ★ $397.32 |
| AVG Volume (30 Days) | ★ 8.8M | 2.3M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | 1.88% | ★ 2.16% |
| EPS Growth | N/A | ★ 88.23 |
| EPS | N/A | ★ 7.71 |
| Revenue | N/A | ★ $25,424,000,000.00 |
| Revenue This Year | $2.08 | $6.04 |
| Revenue Next Year | $8.89 | $3.63 |
| P/E Ratio | ★ $11.21 | $60.60 |
| Revenue Growth | N/A | ★ 8.83 |
| 52 Week Low | $9.96 | $294.58 |
| 52 Week High | $15.05 | $475.65 |
Technical Indicators
Market Signals| Indicator | SAN | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 27.97 | 72.51 |
| Support Level | $10.44 | $338.03 |
| Resistance Level | $11.55 | N/A |
| Average True Range (ATR) | 0.23 | 10.15 |
| MACD | -0.16 | 3.30 |
| Stochastic Oscillator | 15.07 | 86.53 |
Price Performance
Historical ComparisonAbout SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander runs five global businesses: retail and commercial banking, corporate and investment banking, wealth management and insurance, payments, and a digital platform Openbank. Spain is the largest single profit contributor, followed by Brazil, the United States, Mexico and the United Kingdom.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.